Patents are the first line of defence for biotechs. But in radiopharmaceutical medicine it's *doctors* that hold the whip hand because they make the goods. In Australia they are going up against Novartis in the name of patient access. Hear all about it on episode 5 of NUKED #biosky

NUKED: Patent puzzles, with FB Rice - Phase III

The rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of your product is not made...